INTERNATIONAL PATENT: INTELLIA THERAPEUTICS, INC. FILES APPLICATION FOR "NUCLEASE RESISTANT DOUBLE STRANDED DNA PRODUCT FOR NON-VIRAL DELIVERY TO A CELL AND METHODS OF PRODUCTION THEREOF"

GENEVA, April 1 -- INTELLIA THERAPEUTICS, INC. (40 Erie StreetCambridge, Massachusetts 02139) filed a patent application (PCT/US2024/047029) for "NUCLEASE RESISTANT DOUBLE STRANDED DNA PRODUCT FOR NON-VIRAL DELIVERY TO A CELL AND METHODS OF PRODUCTION THEREOF" on Sep 17, 2024. With publication no. WO/2025/064396, the details related to the patent application was published on Mar 27, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): KRAMER, Tal (c/o Intellia Therapeutics, Inc.40 Erie StreetCambridge, Massachusetts 02139), KISHOR, Aparna (c/o Intellia Therapeutics, Inc.40 Erie StreetCambridge, M...